Document:

Exhibit 10.5

                      RECISSION AND REIMBURSEMENT AGREEMENT

     THIS RECISSION AND REIMBURSEMENT AGREEMENT (this "Agreement"), dated this
20th day of April, 2000, is by and among Solar Satellite Communication, Inc.,
a Colorado corporation, Stephen A. Maguire, Robert J. Guerra, and Craig A.
Kleinman.

1. DEFINITIONS Throughout this Agreement, and unless the context otherwise
requires, the word or words set forth below within the quotation marks shall be
deemed to mean the words which follow them:

     1.1. "Act" means The Investment Company Act of 1940, US Code, Title 15,
Sections 8a et seq.

     1.2. "Appointment Date" means July 8, 1998.

     1.3. "Company" means Solar Satellite Communication, Inc., a Colorado
corporation whose principal business address is 6300 S. Syracuse Way, suite 293,
Englewood, Colorado 80111.

     1.4. "Directors" means, collectively, Stephen A. Maguire, Robert J. Guerra,
and Craig A. Kleinman.

     1.5. "Effective Date" means January 7, 1999.

     1.6. "Government Rate" means four and one-half percent per annum.

     1.7. "Investment Securities" has the meaning set forth in Section
80a-3(a)(2) of the Act.

     1.8. "Reimbursement Date" means April 30, 2000.

     1.9. "Remaining Securities" means the following described securities that
the Company was holding as of October 31, 1999:

         Name of Security                               No. of Shares
         ----------------                               -------------

         4Front Technologies, Inc.                          2,500
         Iomega Corporation                                30,000
         Brookline Bancorp, Inc.                            5,000
         Boston life Sciences, Inc.                        10,000

2. RECITALS

     2.1. Since the Appointment Date, the Directors have continuously served as
the sole Directors of the Company.

                                   Page 1 of 4

<PAGE>

     2.2. Between the Effective Date and August 4, 1999, the officers of the
Company, pursuant to the authorization of the Directors, purchased certain
Investment Securities in the Company name.

     2.3. The Company may have been prohibited under the Act from buying and
selling Investment Securities.

     2.4. At the time the Directors authorized the Company officers to purchase
Investment Securities they were unaware that such purchases may have violated
the Act.

     2.5. The Company and the Directors desire, by this Agreement, to revoke and
rescind, ab initio, the Company's acquisition of the Investment Securities.

     2.6. The Company has incurred up to the date of this Agreement an aggregate
loss on the Investment Securities.

     2.7. The Company and the Directors are entering into this Agreement to set
forth the parties' rights and obligations with respect to the Investment
Securities acquired in the Company's name and in the Company's brokerage
accounts since the Effective Date.

     NOW THEREFORE, in consideration of the mutual covenants and agreements
herein set forth and for other good and valuable consideration, the receipt and
sufficiency of which are hereby expressly confessed and acknowledged, the
parties hereto do hereby covenant and agree as follows:

3. RECISSION AND REIMBURSEMENT

     3.1. Recission. The Company and the Directors hereby agree that the
purchase by the Company of all Investment Securities shall be rescinded and, on
or before the Reimbursement Date, the assets of the Company shall be restored to
a position no less favorable than they would have been in as of the
Reimbursement Date if the Investment Securities had not been purchased.

     3.2. Sale of Securities. All remaining Investment Securities shall be sold
by the Company as rapidly as practicable and in any event on or before the
Reimbursement Date.

     3.3. Reimbursement. The Directors jointly and severally shall reimburse the
Company on or before the Reimbursement Date for (i) the aggregate loss the
Company incurred on the Investment Securities up to the Reimbursement Date (or
for any aggregate profit which may be subsequently realized prior to the
Reimbursement Date) and (ii) interest on all amounts expended for the purchase
of the Investment Securities for the period that the Investment Securities were
held at the Government Rate less any dividends or interest realized by the
Company on the Investment Securities.

     3.4. October 31, 1999 Balances. The Company and the Directors acknowledge
that as of October 31, 1999 the Company had an outstanding aggregate investment

                                   Page 2 of 4

<PAGE>

in the Investment Securities of $290,937.87 and that as of that date the
obligation of the Directors for the reimbursement of interest to the Company at
the Government Rate was $ . The foregoing interest reimbursement obligation was
computed by applying proceeds from the sales of the Investment Securities prior
to October 31, 1999 first to interest and then to the amounts expended for the
purchase of the Investment Securities, with the amount applied to interest prior
to October 31, 1999 amounting to $15,580.58.

     3.5. Financial Statements. The Company and Directors acknowledge and agree
that because of the matters recited in Section 2 above and the resulting
recession and reimbursement obligation of the Directors the financial statements
of the Company as of October 31, 1999 do not reflect ownership of the Investment
Securities by the Company and do reflect the obligation of the Directors to
reimburse the Company for all amounts expended by the Company for the Investment
Securities and for interest thereon at the Government Rate.

4. GENERAL PROVISIONS.

     4.1. Agreement Not in Conflict with Other Instruments. This Agreement
contains the entire understanding between the parties hereto with respect to the
transactions contemplated herein and such understanding shall not be modified
except in writing signed by or on behalf of the parties hereto.

     4.2. Interpretation and Severability. Wherever possible, each provision of
this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law. Should any portion of this Agreement be declared invalid
for any reason in any jurisdiction, such declaration shall have no effect upon
the remaining portions of this Agreement. Furthermore, the entirety of this
Agreement shall continue in full force and effect in all other jurisdictions and
such remaining portions of this Agreement shall continue in full force and
effect in the subject jurisdiction as if this Agreement had been executed with
the invalid portions thereof deleted.

     4.3. Colorado Law. This Agreement is and shall be deemed to be a contract
entered into and made pursuant to the laws of the State of Colorado and shall in
all respects be governed, construed, applied and enforced in accordance with the
laws of said state.

     4.4. Section Headings. The section headings herein are included for
convenience only and shall not be deemed to be a part of this Agreement.

                                   Page 3 of 4

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Escrow Agreement
as of the date first set forth adjacent to their names.

DIRECTORS:

DATE: May 1, 2000                       /s/ Stephen A. Maguire
     -----------------------------      ----------------------------------------
                                        Stephen A. Maguire

DATE: May 1, 2000                       /s/ Robert J. Guerra
     -----------------------------      ----------------------------------------
                                        Robert J. Guerra

DATE: May 1, 2000                       /s/ Craig A. Kleinman
     -----------------------------      ----------------------------------------
                                        Craig A. Kleinman

COMPANY:                                SOLAR SATELLITE COMMUNICATION, INC,
                                        a Colorado corporation

DATE: May 1, 2000                       By:  /s/ Robert J. Guerra
     -----------------------------           -----------------------------------
                                             Name: Robert J. Guerra
                                             Title:   President

                                   Page 4 of 4CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT

We consent to the use in this  Registration  Statement  on Form  10-KSB/A of our
report  included  herein  dated March 20,  2000,  relating  to the  consolidated
financial statements of Medsearch Technologies, Inc. and subsidiaries.

Kempisty & Company
Certified Public Accountants PC
New York, NY
July 24, 2000CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT

We consent to the use in this Registration Statement on Form 10-SB/A of our
report included herein dated March 20, 2000, relating to the consolidated
financial statements of Medsearch Technologies, Inc. and subsidiaries.

Kempisty & Company
Certified Public Accountants PC
New York, NY
July 24, 2000EXHIBIT 10.1

RESOLUTION AUTHORIZING ISSUANCE OF SHARES

The Board of Directors of the Company authorizes the Company to register Five
Hundred Thousand (500,000) shares of the Company with the Securities and
Exchange Commission by filing a Form S-1 with the Commission. Further, the Board
has authorized the filing of Forms U-1 and U-2 with the appropriate regulatory
authorities of each state to comply with applicable Blue Sky laws.

I, Debra B. Krahling, Secretary of the Corporation, do hereby certify that the
above is a true and correct statement of the resolution unanimously approved by
the Board of Directors on February 26, 2000 and affix the corporate seal hereto.

DATED: February 26, 2000

(SEAL)   SciCorps, Inc.

       DEBRA B. KRAHLING
By: ___________________________________
       DEBRA B. KRAHLING
       SECRETARYEXHIBIT 10.2

COMMON STOCK BARTER AGREEMENT

In exchange for the following listed considerations, SciCorps, Inc. agrees to
the issue and transfer of 750,000,000 shares of its Common Stock with no par
value to Daniel R. Thomas. This stock shall hereafter be known as "Founder's
Stock". The following listed considerations shall be deemed payment in full for
the aforementioned Founder's Stock. When this agreement is duly signed by the
President and the Secretary of SciCorps, Inc. and imprinted with its official
corporate seal, it will constitute the full and complete agreement regarding the
aforementioned Founder's Stock and the exchange of considerations between Daniel
R. Thomas and SciCorps, Inc. The 750,000,000 shares of Common Stock referred to
in this agreement shall be deemed duly authorized, validly issued, fully paid,
and non-assessable common shares in the capital of SciCorps, Inc.

The complete list of considerations consist of the following 22 items:

01: Assignment in toto of the intellectual property rights to the

                                       48
<PAGE>
invention, "Anti-Telomerase", and to the concomitant telomere stabilization
factors by the inventor, Daniel R. Thomas, MD, PhD. Value assigned to this
invention and its derivatives: $500,000,000

02: Assignment in toto of the intellectual property rights to the invention, "A
Chimeric Gene Assembly Protocol", by the inventor, Daniel R. Thomas, MD, PhD.
Value assigned to this invention and its derivatives: $500,000,000

03: Assignment in toto of the intellectual property rights to the invention, "A
Novel Treatment for Malignant Neoplastic Tissue Utilizing Conjugated Monoclonal
Antibodies as Electromagnetically Activated Hyperthermic Vectors" by the
inventor, Daniel R. Thomas, MD, PhD. Value assigned to this invention and its
derivatives: $500,000,000

04: Assignment in toto of the intellectual property rights to the invention, "A
Hydrolytic Fission Reactor" by the inventor, Daniel R. Thomas, MD, PhD. Value
assigned to this invention and its derivatives: $500,000,000

05: Assignment in toto of the intellectual property rights to the invention, "A
Low-Voltage Plasma Maser" by the inventor, Daniel R. Thomas, MD, PhD. Value
assigned to this invention and its derivatives: $500,000,000

06: Assignment in toto of the intellectual property rights to the invention, "A
High Efficiency Hydrolytic Propulsion Unit" by the inventor, Daniel R. Thomas,
MD, PhD. Value assigned to this invention and its derivatives: $1,000,000,000

07: Assignment in toto of the intellectual property rights to the family of
inventions that fall under the rubric of "Mitochondrial Enhancers" by the
inventor, Daniel R. Thomas, MD, PhD. Value assigned to this invention and its
derivatives: $500,000,000

08: Assignment in toto of the intellectual property rights to the invention,
"BioSoft/WetWare: A CPU-Neuronal Interface System: A Cybernetic Bio-Programming
Language and Translation Driver" by the inventor, Daniel R. Thomas, MD, PhD.
Value assigned to this invention and its derivatives: $1,000,000,000

09: Assignment in toto of the intellectual property rights to the invention, "A
Novel Gene Splicing Tool", by the inventor, Daniel R. Thomas, MD, PhD. Value
assigned to this invention and its derivatives: $500,000,000

10: Assignment in toto of the intellectual property rights to the

                                       49
<PAGE>
invention, "A New Cryogenic Preservation Technology based on a Proprietary
Synthetic Hybrid of Naturally Occurring Glycols", by the inventor, Daniel R.
Thomas, MD, PhD. Value assigned to this invention and its derivatives:
$1,000,000,000

11: Assignment in toto of the intellectual property rights to the invention,
"Synthetic and Natural Arachnid Silk Polymers", by the inventor, Daniel R.
Thomas, MD, PhD. Value assigned to this invention and its derivatives:
$1,000,000,000

12: Assignment in toto of the intellectual property rights to the category of
inventions that come under the heading of, "Antibiotics and Antiviral Agents",
by the inventor, Daniel R. Thomas, MD, PhD. Value assigned to this class of
inventions and its derivatives: $1,000,000,000

13: Assignment in toto of the intellectual property rights to the invention,
"Instant Paint-on Dental Whiteners (muco-polymers) [an alternative to bleaching
agents]", by the inventor, Daniel R. Thomas, MD, PhD. Value assigned to this
invention and its derivatives: $500,000,000

14: Assignment in toto of the intellectual property rights to the invention,
"Nucleic Acid Mediated Hair Restoration Treatment (reverses baldness)", by the
inventor, Daniel R. Thomas, MD, PhD. Value assigned to this invention and its
derivatives: $500,000,000

15: Assignment in toto of the intellectual property rights to the invention,
"Nucleic Acid Mediated Scar Removal System", by the inventor, Daniel R. Thomas,
MD, PhD. Value assigned to this invention and its derivatives: $500,000,000

16: Assignment in toto of the intellectual property rights to the invention,
"Functional Hemoglobin Enhancers (increases oxygen binding capacity utilizing a
proprietary amino acid stacking system)", by the inventor, Daniel R. Thomas, MD,
PhD. Value assigned to this invention and its derivatives: $500,000,000

17: Assignment in toto of the intellectual property rights to the invention,
"Neuro-Chemical Sleep Blockers", by the inventor, Daniel R. Thomas, MD, PhD.
Value assigned to this invention and its derivatives: $500,000,000

18: Assignment in toto of the intellectual property rights to the invention,
"Neuro-Chemical Memory Enhancers", by the inventor, Daniel R. Thomas, MD, PhD.
Value assigned to this invention and its derivatives: $1,000,000,000

                                       50
<PAGE>
19: Assignment in toto of the intellectual property rights to the invention,
"Neuro-Chemical Synaptic Enhancers", by the inventor, Daniel R. Thomas, MD, PhD.
Value assigned to this invention and its derivatives: $1,000,000,000

20: Assignment in toto of the intellectual property rights to the class of
inventions that fall under the rubric of, "Neuronal Growth and Control Factors",
by the inventor, Daniel R. Thomas, MD, PhD. Value assigned to this class of
inventions and its derivatives: $1,000,000,000

21: Assignment in toto of the intellectual property rights to the class of
inventions that fall under the rubric of, "Photosynthetic Skin Patches
(Alternative Parenteral Nutritional Supplementation - post GI surgery)", by the
inventor, Daniel R. Thomas, MD, PhD. Value assigned to this class of inventions
and its derivatives: $500,000,000

22: Assignment in toto of the intellectual property rights to the class of
inventions designated "Chloroplast - Mitochondrial Exchange Units", by the
inventor, Daniel R. Thomas, MD, PhD. Value assigned to this class of invention
and its derivatives: $500,000,000

NOTES

The intellectual property ascribed to Dr. Thomas is understood to be unvetted,
untested, unpatented, and merely theoretical in nature. It is understood that
Dr. Thomas will assist SciCorps, Inc. to the best of his abilities in vetting,
testing, developing, and patenting the above ascribed inventions and
technologies. It is also understood that Dr. Thomas is making the aforementioned
assignments to SciCorps, Inc. on an exclusive basis and relinquishes all rights
in the previously mentioned inventions and technologies. Dr. Thomas further
agrees to refrain from the pursuit and development of other inventions and
technologies that would serve to compete with the aforementioned inventions and
technologies.

Date: February 1, 2000

This agreement is signed this day by the following parties:

DANIEL R. THOMAS
_______________________________________________

DANIEL R. THOMAS, MD, PhD, Inventor

                                       51
<PAGE>
DANIEL R. THOMAS
_______________________________________________
DANIEL R. THOMAS
President of SciCorps, Inc.

DEBRA B. KRAHLING
________________________________________________
DEBRA B. KRAHLING
Secretary of SciCorps, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]